top of page

C3 Team Members

Dr. Rebecca Auer

Dr. Rebecca Auer

C3 HOPE Lead

Christine Lafontaine

Christine Lafontaine

C3 HOPE Research Navigator

Dr. Carolina Ilkow

Dr. Carolina Ilkow

C3 IMPACT and C3 IMPACT-OV Lead

Lead for C3 IMPACT

Dr. Rachel Goodwin

Dr. Rachel Goodwin

C3 HOPE-Rounds

Dr. Samar Attieh

Dr. Samar Attieh

C3 HOPE Study

Dr. John Bell

Dr. John Bell

C3 STAR-C
C3 IMPACT

C3 Team Mentor and Scientific Advisor

Dr. Sandy Pelletier

Dr. Sandy Pelletier

C3 STAR-C Cell Manufacturing (Montreal)

Montreal Cell Manufacturing of TIL products Lead

Dr. Rebecca Auer

Dr. Rebecca Auer

Cheffe du C3 ESPOIR

Lead for the overall C3 Program and oversees the Research Navigator and C3-HOPE

Dr. Simon Turcotte

Dr. Simon Turcotte

C3 STAR-C Lead

Lead for STAR-C Clinical Trial

Dr. Carmen Loiselle

Dr. Carmen Loiselle

C3 HOPE Study

Dr. Leonard Angka

Dr. Leonard Angka

C3 Program Manager

Managing the milestones and deliverables of the C3 program initiatives

Dr. Carmen Loiselle

Dr. Carmen Loiselle

Étude C3 ESPOIR

Lead for the C3 Hope Study and expert in qualitative interviewing.

Dr. Samar Attieh

Dr. Samar Attieh

Étude C3 ESPOIR

C3 Hope Study

Dr. Mathieu Crupi

Dr. Mathieu Crupi

C3 STAR-C Cell Manufacturing (Ottawa)

C3 Cell Manufacturing Team (Ottawa)

Dr. Rebecca Auer

Dr. Rebecca Auer

Melinda Bachini

Melinda Bachini

C3 HOPE - Patient Advocate

Christine Lafontaine

Christine Lafontaine

Navigatrice de recherche du C3 ESPOIR

Helping patients and caregivers navigate through the complex journey after cancer diagnosis

Melinda Bachini

Melinda Bachini

Défenseur des patients du C3 ESPOIR

C3 HOPE - Patient Advocate

Dr. Rachel Goodwin

Dr. Rachel Goodwin

Réunions cliniques du C3 ESPOIR

Co-Chair for Multidisciplinary Cholangiocarcinoma Rounds

Dr. Jennifer Quizi

Dr. Jennifer Quizi

C3 STAR-C

Ottawa Cell Manufacturing of TIL products Lead

  • Facebook
  • Instagram
  • LinkedIn
  • Youtube
  • Twitter
logoImage.png
leaf-cihr-colour-en_edited.png

The Canadian Cholangiocarcinoma Collaborative (C3) is supported by a Canadian Cancer Society Breakthrough Team Grant in partnership with the Canadian Institutes of Health Research. The granting funds for C3 are managed by The Ottawa Hospital Research Institute, which serves as the lead institute for all collaborative operations.

© 2025 www.cholangio.ca. All rights reserved.

bottom of page